Lack of somatic mutations in VEGFR-2 tyrosine kinase domain in hepatocellular carcinoma

By Chuah Benjamin   Yeo Wee-Lee   Guo Jia Yi   Lim Seng-Gee   Yap Hui-Ling   Goh Boon-Cher   Lee Soo-Chin  

Acta Oncologica, Vol. 48, Iss. 4, 2009-05 ,pp. : 628-630

Informa Healthcare

Access to resources Recommend Favorite

Receptor tyrosine kinase alterations and therapeutic opportunities in squamous cell carcinoma of the lung

By Wang Dong   Du Licheng   Liu Qi   Liu Xiangyan   Wang Zhou  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 4, 2013-10 ,pp. : 725-731

Springer Publishing Company

Access to resources Recommend Favorite

Targeting JAK3 Tyrosine Kinase-Linked Signal Transduction Pathways with Rationally-Designed Inhibitors

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 7, Iss. 6, 2007-11 ,pp. : 612-623

Bentham Science Publishers

Access to resources Recommend Favorite

Tyrosine Kinase Inhibitor PTK/ZK Enhances the Antitumor Effects of Interferon-α/5-Fluorouracil Therapy for Hepatocellular Carcinoma Cells

By Murakami Masahiro  

Annals of Surgical Oncology, Vol. 18, Iss. 2, 2011-02 ,pp. : 589-596

Springer Publishing Company

Access to resources Recommend Favorite

High Expression of Proline-Rich Tyrosine Kinase2 is Associated with Poor Survival of Hepatocellular Carcinoma via Regulating Phosphatidylinositol 3-Kinase/AKT Pathway

By Cao Jie   Chen Yao   Fu Jing   Qian You-Wen   Ren Yi-Bin   Su Bo   Luo Tao   Dai Rong-Yang   Huang Liang   Yan Jian-Jun   Wu Meng-Chao   Yan Yi-Qun   Wang Hong-Yang  

Annals of Surgical Oncology, Vol. 20, Iss. 3, 2013-12 ,pp. : 312-323

Springer Publishing Company

Access to resources Recommend Favorite